These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38142847)

  • 1. Dual antithrombotic therapy dose-dependently alters hemostatic plug structure and function.
    Mansi CD; Severa JR; Wilhelm JN; Marar TT; Roberts ME; Zhao X; Stalker TJ
    J Thromb Haemost; 2024 Apr; 22(4):1016-1023. PubMed ID: 38142847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
    Galli M; Franchi F; Rollini F; Been L; Jaoude PA; Rivas A; Zhou X; Jia S; Maaliki N; Lee CH; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Geisler T; Jennings LK; Bass TA; Angiolillo DJ
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):728-737. PubMed ID: 35353154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
    Wong PC; Crain EJ; Watson CA; Wexler RR; Lam PY; Quan ML; Knabb RM
    J Thromb Thrombolysis; 2007 Aug; 24(1):43-51. PubMed ID: 17323133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
    Hosokawa K; Ohnishi T; Sameshima H; Miura N; Koide T; Maruyama I; Tanaka KA
    PLoS One; 2014; 9(1):e86491. PubMed ID: 24497951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel mouse hemostasis model for real-time determination of bleeding time and hemostatic plug composition.
    Getz TM; Piatt R; Petrich BG; Monroe D; Mackman N; Bergmeier W
    J Thromb Haemost; 2015 Mar; 13(3):417-25. PubMed ID: 25442192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects.
    Traby L; Kollars M; Kaider A; Eichinger S; Wolzt M; Kyrle PA
    J Thromb Haemost; 2016 Feb; 14(2):273-81. PubMed ID: 26663880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
    Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
    Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of bleeding risk of interventional techniques: a best evidence synthesis of practice patterns and perioperative management of anticoagulant and antithrombotic therapy.
    Manchikanti L; Falco FJ; Benyamin RM; Caraway DL; Kaye AD; Helm S; Wargo BW; Hansen H; Parr AT; Singh V; Swicegood JR; Smith HS; Schultz DM; Malla Y; Hirsch JA
    Pain Physician; 2013 Apr; 16(2 Suppl):SE261-318. PubMed ID: 23615893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease.
    Coleman CI; Kharat AA; Bookhart B; Baker WL
    Curr Med Res Opin; 2022 Jan; 38(1):27-34. PubMed ID: 34641745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis.
    Zhang J; Chen Z; Cai Y; Li C; He Y
    Cardiovasc Ther; 2023; 2023():5446271. PubMed ID: 37636560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats.
    Schumacher WA; Bostwick JS; Ogletree ML; Stewart AB; Steinbacher TE; Hua J; Price LA; Wong PC; Rehfuss RP
    J Pharmacol Exp Ther; 2007 Jul; 322(1):369-77. PubMed ID: 17420297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.
    Nylander S; Wågberg F; Andersson M; Skärby T; Gustafsson D
    J Thromb Haemost; 2015 Aug; 13(8):1494-502. PubMed ID: 26096765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y
    Li X; Liu P; Xu Z; Sun D; Gu J; Miao Y; Zhang J; Cao X
    Cardiovasc Drugs Ther; 2020 Feb; 34(1):15-23. PubMed ID: 32062793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents.
    Honda Y; Kamisato C; Morishima Y
    Eur J Pharmacol; 2016 Sep; 786():246-252. PubMed ID: 27288116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.
    Galli M; Franchi F; Rollini F; Been L; Jaoude PA; Rivas A; Zhou X; Jia S; Maaliki N; Lee CH; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Geisler T; Jennings LK; Bass TA; Angiolillo DJ
    Thromb Haemost; 2022 Aug; 122(8):1341-1351. PubMed ID: 34983074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualized antithrombotic therapy.
    Lüscher TF; Steffel J
    Hamostaseologie; 2016; 36(1):26-32. PubMed ID: 25597592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic inhibitory effects of clopidogrel and rivaroxaban on platelet function and platelet-dependent thrombin generation in cats.
    Lo ST; Li RHL; Georges CJ; Nguyen N; Chen CK; Stuhlmann C; Oldach MS; Rivas VN; Fousse S; Harris SP; Stern JA
    J Vet Intern Med; 2023; 37(4):1390-1400. PubMed ID: 37208839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on platelet function of a direct acting antagonist of coagulation factor Xa.
    Ringwala SM; Dibattiste PM; Schneider DJ
    J Thromb Thrombolysis; 2012 Oct; 34(3):291-6. PubMed ID: 22528328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study.
    Jackson LR; Ju C; Zettler M; Messenger JC; Cohen DJ; Stone GW; Baker BA; Effron M; Peterson ED; Wang TY
    JACC Cardiovasc Interv; 2015 Dec; 8(14):1880-9. PubMed ID: 26718518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.